Patients with one flare or less (n = 5) | Patients with more than a flare (n = 8) | p-value | |
---|---|---|---|
Age, mean (SD), years | 40.8 ± 15.7 | 52.9 ± 12.5 | NS |
Female, n (%) | 3 (60%) | 6 (75%) | NS |
Disease duration, mean (SD), years | 12.4 ± 8.7 | 10.9 ± 10.4 | NS |
TCZ exposure before tapering, months (SD) | 16.4 ± 8.8 | 20.4 ± 5.7 | NS |
Remission achievement delay, months (SD) | 3 ± 2.4 | 2 ± 2.8 | NS |
Remission duration, months (SD) | 5.6 ± 2.8 | 8.8 ± 7.5 | NS |
RF positive, n (%) | 0 (0%) | 7 (87.5%) | 0.004 |
ACPA positive, n (%) | 0 (0%) | 7 (87.5%) | 0.004 |
Erosive status, n (%) | 3 (60%) | 7(87.5%) | NS |
Previous number of sDMARDs | 1.8 ± 0.8 | 2.4 ± 1 | NS |
Previous number of bDMARDs | 1.6 ± 1.1 | 1.75 ± 1.3 | NS |
Swollen joint count | 0 | 0.125 ± 0.3 | NS |
Tender joint count | 2.4 ± 4.3 | 3.6 ± 2.97 | NS |
Hyperhemia at Doppler | 0 (0%) | (37.5%) | NS |
Number of patients with active synovitis | 3 (60%) | 4(50%) | NS |
Number of active synovitis | |||
Hands | 3 | 11 | NS |
Feet | 2 | 3 | NS |
Concomitant therapy | |||
MTX, n (%) | 3 (60%) | 3 (37.5%) | NS |
LEF, n (%) | 1 (20%) | 2 (25%) | NS |
Flare, mean (SD) | 0.6 ± 0.5 | 2.13 ± 0.35 | 0.001 |